Skip to main content

ADVERTISEMENT

Abstracts

Background EGFR antibodies are efficient in the treatment of patients with RAS wild type metastatic colorectal cancer (mCRC). However, 25% of those patients resist to th...
06/27/2022
Background Colorectal cancer is a real public health problem, it ranks third among cancers in terms of frequency the world and second in terms of mortality. Several envi...
06/27/2022
Background Anlotinib, a novel multi-targeting tyrosine kinase inhibitor (TKI), has been investigated in a variety of malignant tumors and has shown efficacy in clinical ...
06/27/2022
Background There is a strong body of evidence supporting use of immune checkpoint inhibitors (ICI) in unresectable mismatch repair-deficient (MMRd) / microsatellite unst...
06/27/2022
Background The variability of gene expression signatures across tumor sites has been previously documented [Stewart et al. 2017]. However, how this information can be ex...
06/27/2022
Background Gastric cancer is associated with poor prognosis. Curative resection alone leads to a dismal outcome of gastric and GEJ adenocarcinoma. In the western gastric...
06/27/2022
Background Death association protein-3 (DAP3) is an important growth/death regulator of cells, has been found to have important clinical value in various cancer. DELE1 (...
06/27/2022
Background One common genetic factor affecting the colorectal cancer (CRC) development and the outcome is the mutational status of the RAS gene family. Somatic variants ...
06/27/2022
Background Detection of MRD has emerged as a tool for risk stratification in patients with early stage CRC with potential implication for adjuvant therapy. Recently, the...
06/27/2022
Background Pancreatic ductal adenocarcinoma (PDAC) represents the majority of diagnosed pancreatic cancers and its mortality rates are well above 90%. This bleak scenari...
06/27/2022